Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia

Biomarker Research
Desiree KunadtFriedrich Stölzel

Abstract

Lysyl oxidase (LOX) has been described as necessary for premetastatic niche formation in epithelium-derived malignancies and its expression level therefore correlates with risk of metastatic disease and overall survival. However, its role in acute myeloid leukemia (AML) has not been sufficiently analyzed. We investigated LOX plasma expression in 683 AML patients (age 17-60 years) treated within the prospective AML2003 trial (NCT00180102). The optimal cut-off LOX value was determined using a minimal-p-value method dichotomizing patients into a LOX-high group (> 109 ng/mL, n = 272, 40%) and a LOX-low group (≤ 109 ng/mL, n = 411, 60%). Higher LOX expression was associated with lower peripheral white blood cells, lower serum LDH, and a lower frequency of FLT3-ITD and NPM1 mutations at diagnosis. Higher LOX expression was found significantly more frequently in patients with secondary AML and therapy-related AML, in patients with French-American-British M5 subtypes, and in patients with adverse-risk cytogenetics. Comparing patients in the LOX-high group and the LOX-low group revealed a 3-year overall survival (OS) of 47 and 53% (p = 0.022) and 3-year event-free survival (EFS) of 27 and 35% (p = 0.005), respectively. In the LOX-high g...Continue Reading

References

Nov 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·M A Cifone, I J Fidler
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC D Bloomfield
Feb 22, 2001·Journal of the National Cancer Institute·M Höckel, P Vaupel
Jan 10, 2002·Analytical Biochemistry·Amitha H Palamakumbura, Philip C Trackman
Aug 30, 2003·Oncogene·Nicholas C DenkoAmato J Giaccia
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Feb 19, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin S TallmanUNKNOWN Eastern Cooperative Oncology Group
Aug 5, 2005·Genes, Chromosomes & Cancer·George DeebRichard T Cheney
Nov 18, 2006·Cell·Gaorav P Gupta, Joan Massagué
Mar 1, 2008·Proceedings of the National Academy of Sciences of the United States of America·Ramiro GarzonBrunangelo Falini
Oct 18, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Andreas K BuckSven N Reske
Jul 29, 2009·Blood·Michael StefanidakisErkki Koivunen
May 20, 2011·Nature·Peter Carmeliet, Rakesh K Jain
Jun 21, 2011·Haematologica·Friedrich StölzelMarkus Schaich
Jun 28, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Melhem SolhDan S Kaufman
Jul 29, 2011·Blood·Richard L BakstJoachim Yahalom
May 29, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Satoshi YoshiharaHiroyasu Ogawa
Jul 7, 2012·Blood·Nikolaos PapadantonakisKatya Ravid
Jan 3, 2013·International Journal of Cancer. Journal International Du Cancer·Maro OhanianZeev Estrov
Jan 25, 2013·Cancer Research·Thomas R CoxJanine T Erler
Mar 16, 2013·American Journal of Hematology·T TadmorZ Vadasz
May 1, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus SchaichGerhard Ehninger
Mar 13, 2017·Journal of Biotechnology·Camron S DawesChien-Chi Lin

❮ Previous
Next ❯

Methods Mentioned

BETA
deamination
Assay
MDS
PCR

Clinical Trials Mentioned

NCT00180102

Software Mentioned

SPSS
R

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.